WINT · Windtree Therapeutics Inc /De/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.90M | $2.18M | $2.27M | - | $1.97M | $9.86M | $2.25M | - | $2.11M | $1.76M |
| SG&A | $2.77M | $1.59M | $1.82M | - | $2.77M | $1.59M | $2.15M | - | $2.58M | $2.42M |
| Total Operating Expenses | $19.88M | $3.98M | $4.09M | - | $4.74M | $11.45M | $4.41M | - | $4.69M | $6.76M |
| D&A | - | - | $17.0K | - | - | - | $21.0K | - | - | - |
| Operating Income | ($19.88M) | ($3.98M) | ($4.09M) | - | ($4.74M) | ($11.45M) | ($4.41M) | - | ($4.69M) | ($6.76M) |
| Interest Expense | $328.0K | $79.0K | $13.0K | - | $51.0K | $110.0K | $13.0K | - | $13.0K | $13.0K |
| Income Tax | ($3.43M) | $0 | $0 | - | ($240.0K) | $0 | $114.0K | - | - | - |
| Net Income | ($28.09M) | ($10.63M) | ($4.04M) | - | ($2.75M) | ($12.02M) | $10.22M | - | ($4.42M) | ($6.60M) |
| EPS - Basic | ($1.08) | ($3.06) | ($4.63) | - | ($211.50) | ($1045.50) | $1099.00 | - | ($774.00) | ($1476.00) |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $204.0K | $301.0K | $1.17M | $1.78M | $2.30M | $1.80M | $2.55M | $4.32M | $7.37M | $11.47M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.65M | $4.12M | $3.11M | $1.88M | $2.05M | $2.97M | $1.69M | $809.0K | $944.0K | $964.0K |
| Current Assets | $7.21M | $6.79M | $1.59M | $2.57M | $3.93M | $2.06M | $3.34M | $5.38M | $8.91M | $13.32M |
| Total Assets | $15.98M | $31.83M | $26.77M | $27.88M | $30.45M | $28.71M | $30.10M | $32.41M | $36.06M | $40.58M |
| Current Liabilities | $21.90M | $15.72M | $6.48M | $5.72M | $14.43M | $8.78M | $4.99M | $4.00M | $3.71M | $3.79M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.58M | $24.98M | $15.44M | $14.70M | $23.90M | $18.26M | $14.68M | $29.02M | $28.57M | $28.97M |
| Stockholders' Equity | ($11.61M) | $3.61M | $10.29M | $10.00M | $4.41M | $3.49M | $15.42M | $3.39M | $7.48M | $11.60M |
| Retained Earnings | ($889.37M) | ($861.29M) | ($850.65M) | ($846.61M) | ($848.81M) | ($846.63M) | ($834.60M) | ($844.82M) | ($839.67M) | ($835.24M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($2.41M) | - | - | - | ($2.95M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $1.80M | - | - | - | $1.03M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | 1.1% | - | - | - |
| Return on assets | -175.7% | -33.4% | -15.1% | - | -9.0% | -41.9% | 33.9% | - | -12.3% | -16.3% |
| Return on equity | 241.9% | -294.8% | -39.3% | - | -62.3% | -344.1% | 66.3% | - | -59.1% | -56.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.33 | 0.43 | 0.25 | 0.45 | 0.27 | 0.23 | 0.67 | 1.35 | 2.40 | 3.51 |
| Quick ratio | 0.33 | 0.43 | 0.25 | 0.45 | 0.27 | 0.23 | 0.67 | 1.35 | 2.40 | 3.51 |
| Cash ratio | 0.01 | 0.02 | 0.18 | 0.31 | 0.16 | 0.21 | 0.51 | 1.08 | 1.99 | 3.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -60.6x | -50.4x | -314.6x | - | -93.0x | -104.1x | -338.8x | - | -360.8x | -519.8x |
| Equity multiplier | -1.38 | 8.83 | 2.60 | 2.79 | 6.91 | 8.22 | 1.95 | 9.56 | 4.82 | 3.50 |
| Liabilities / Assets | 1.73 | 0.78 | 0.58 | 0.53 | 0.78 | 0.64 | 0.49 | 0.90 | 0.79 | 0.71 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -319.4% | 65.2% | 7.2% | - | -1.1% | -69.5% | -5.1% | - | -0.9% | 61.5% |
| Net income growth (YoY) | -921.6% | 11.6% | - | - | 37.9% | -82.2% | - | - | -9.1% | 61.9% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 3.2% | -33.3% | 194.8% | -41.1% | -69.9% | 119.4% | -66.1% | -57.0% | -39.6% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing WINDTREE THERAPEUTICS INC /DE/ against the 5 most active filers in the same SIC group.